cabazitaxel and Uterine-Cervical-Neoplasms

Taxane-based chemotherapeutics are clinically available as frontline treatment regimens for cervical cancer. However, drug resistance and life-threatening toxicity impair the clinical efficacy of taxanes, so more effective and less toxic therapeutic modalities are urgently needed. Cabazitaxel has attracted increasing interest due to its potential to circumvent the drug resistance by taxanes. We previously showed that tethering docosahexaenoic acid (DHA) to cabazitaxel enabled the prodrug to self-assemble into nanoparticles in water. Despite this encouraging finding, the DHA-cabazitaxel conjugate formulation requires further optimization to enhance nanoparticle retention and tumor delivery. We here integrated this conjugate into amphiphilic poly(ethylene glycol)-

Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Docetaxel; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Prodrugs; Rats; Rats, Sprague-Dawley; Taxoids; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays